Moderna Inc. has published a document detailing a study on mRNA-encoded masked IL-12, showcasing its potential as a safe and effective immunotherapy. The study highlights the approach of using CytomX's PROBODY® Therapeutics masking technology alongside Moderna's mRNA platform to improve systemic tolerability and maintain anti-tumor efficacy in preclinical models. The full document can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.